The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

The lawsuits come amid several recent studies showing a link between vision complications and people taking drugs ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...

The Daily Aus (TDA) has announced the launch of Investigating Ozempic — an original podcast series examining the complex world of medicated weight loss. Hosted and produced by TDA’s features ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the company. The Danish pharmaceutical giant announced Friday that ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Ozempic users find that it not only promotes weight loss but also helps lower the risk of heart disease, high blood pressure, type 2 diabetes, and other obesity-related conditions.

Lars Fruergaard Jørgensen said he was “surprised” that the Ozempic-maker’s largest shareholder, the Novo Nordisk Foundation, had decided to remove him. “I did not see this coming,” he ...

In a compelling discussion titled “The Trojan Horse of Indian Healthcare”, panellists Dr. Anoop Misra, Dr. Preetha Reddy, and Dr. Chandrakant Lahariya tackle the growing burden of non ...

(Reuters) -Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to ...